Effect of CYP2C19 genotyping to clopidogrel high reactivity / 中国医师杂志

ABSTRACT

Percutaneous coronary intervention is an important method for the treatment of coronary heart disease. Postoperative dual antiplatelet therapy is an important prerequisite to ensure the safety of surgery. Antiplatelet therapy with clopidogrel still has a high risk of thrombosis, which may be related to CYP2C19 genotyping. Therefore, a brief review of the impact of CYP2C19 genotyping on clopidogrel hyperresponsiveness is made.